MYF5 Antibody

What is MYF5 and what is its role in muscle development?

MYF5 (Myogenic Factor 5) is a member of the basic helix-loop-helix (bHLH) transcription factor family that plays a crucial role in skeletal muscle development. The protein functions as a transcriptional activator that promotes the expression of muscle-specific target genes and plays a key role in muscle cell differentiation . MYF5 is essential for precursor cell commitment to the myogenic lineage, and its expression is tightly controlled during muscle cell differentiation .

At the molecular level, MYF5 forms heterodimers with other bHLH proteins such as MyoD, enhancing their function in binding to E-box sequences (CANNTG) in the regulatory regions of muscle-specific genes . This binding facilitates transcriptional activation necessary for proper muscle formation, regeneration, and repair .

What applications are MYF5 antibodies typically used for in research?

MYF5 antibodies are utilized across multiple experimental applications in muscle biology research:

Researchers should verify reactivity with their species of interest, as most commercially available antibodies react with human and mouse MYF5, with cross-reactivity to other species varying by antibody clone .

How do I choose between monoclonal and polyclonal MYF5 antibodies?

The choice between monoclonal and polyclonal MYF5 antibodies depends on your specific research requirements:

Monoclonal MYF5 Antibodies:

• Provide high specificity for a single epitope, reducing background signal

• Offer batch-to-batch consistency for longitudinal studies

• Examples include mouse monoclonal antibodies like clone B-2 (IgG3 kappa) and clone 593128

• Ideal for applications requiring high reproducibility such as flow cytometry and precise quantification

Polyclonal MYF5 Antibodies:

• Recognize multiple epitopes, potentially increasing detection sensitivity

• Provide more robust detection in applications where protein conformation may vary

• Examples include rabbit polyclonal antibodies targeting various regions such as amino acids 21-70

• Better suited for applications where antigen retrieval might be challenging or when the native protein structure is important

For critical experiments, validation with both antibody types may provide complementary data, especially when studying MYF5 in novel contexts or experimental models .

What is the optimal protocol for detecting MYF5 by Western blot?

For optimal MYF5 detection by Western blot, researchers should consider the following methodological approach:

Sample preparation:

• Extract proteins from muscle tissue or cultured cells using RIPA or NP-40 buffer supplemented with protease inhibitors

• Quantify protein concentration (BCA or Bradford assay)

• Load 10-20 μg of total protein per lane

Recommended protocol:

• Separate proteins on 10-12% SDS-PAGE

• Transfer to PVDF or nitrocellulose membrane

• Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

• Incubate with primary MYF5 antibody at recommended dilution (typically 1:500-1:2000 for polyclonal or 1:50000 for high-affinity monoclonal antibodies )

• Wash 3× with TBST

• Incubate with HRP-conjugated secondary antibody

• Develop using ECL or similar detection system

Important considerations:

• MYF5 protein has a predicted molecular weight of 28 kDa, but often appears at ~39 kDa on Western blots due to post-translational modifications

• Include positive controls such as C2C12 mouse myoblast cell lysates or human/mouse skeletal muscle tissue

• Consider using gradient gels (4-15%) if experiencing resolution issues

How can I optimize immunofluorescence staining for MYF5 in muscle tissue or cultured cells?

Optimizing immunofluorescence staining for MYF5 requires attention to fixation, permeabilization, and antibody selection:

For cultured myoblasts (e.g., C2C12 cells):

• Culture cells on glass coverslips coated with gelatin or other appropriate matrix

• Fix cells with paraformaldehyde (4%, 10-15 minutes at room temperature)

• Permeabilize with 0.2-0.5% Triton X-100 or saponin (10 minutes)

• Block with 5% normal serum (from secondary antibody host species) for 1 hour

• Incubate with primary MYF5 antibody (1:200-1:1000 dilution) for 3 hours at room temperature or overnight at 4°C

• Wash 3× with PBS

• Incubate with fluorophore-conjugated secondary antibody (e.g., NorthernLights 557-conjugated)

• Counterstain nuclei with DAPI

• Mount and image using fluorescence microscopy

Key optimization strategies:

• MYF5 shows nuclear localization; ensure proper nuclear permeabilization

• Compare staining patterns between undifferentiated myoblasts and differentiated myotubes to confirm specificity

• When analyzing muscle development, co-staining with other myogenic markers (MyoD, myogenin) can provide valuable contextual information

What are the best approaches for quantifying MYF5-positive cells by flow cytometry?

Flow cytometric analysis of MYF5 requires careful optimization due to its nuclear localization:

Recommended protocol:

• Harvest cells (trypsin or accutase for adherent cells)

• Fix with paraformaldehyde (2-4%) for 10-15 minutes

• Permeabilize membranes with saponin (0.1-0.5%) to allow antibody access to nuclear proteins

• Block with 1-5% BSA or normal serum

• Incubate with primary MYF5 antibody (optimal dilution determined empirically, typically 5-10 μg/mL)

• Wash cells

• Incubate with fluorophore-conjugated secondary antibody (e.g., APC-conjugated anti-mouse IgG)

• Analyze on flow cytometer with appropriate controls

Critical controls include:

• Isotype control antibody (same isotype as primary MYF5 antibody)

• Biological negative control (cell type known not to express MYF5)

• Biological positive control (myoblast cell line like C2C12)

• Single-color controls for compensation when performing multi-color analysis

For analyzing MYF5 in complex tissue samples like primary muscle isolates, consider combining with cell surface markers to identify specific myogenic populations.

How do MYF5 and MyoD differ in their transcriptional activity, and how can antibodies help distinguish their functions?

MYF5 and MyoD show important functional differences despite their structural similarities and overlapping E-box binding properties:

Key functional differences revealed through antibody-based studies:

These differences aren't attributable to DNA binding affinity, as gel shift assays show similar binding kinetics for both factors . Rather, the primary difference lies in MYF5's weaker transcriptional activation domain.

Researchers can exploit these differences by:

• Using ChIP-seq with specific antibodies to map factor binding followed by RNA-seq to correlate binding with transcriptional outcomes

• Employing domain-specific antibodies to study protein-protein interactions that may explain differential activity

• Utilizing chimeric proteins (e.g., MYF5 with MyoD activation domain) to verify functional domain activities

What approaches can be used to study MYF5 in satellite cells and muscle regeneration?

Studying MYF5 in satellite cells and regeneration contexts requires specialized techniques:

Satellite cell isolation and analysis:

• Isolate satellite cells from muscle tissue using fluorescence-activated cell sorting (FACS) or magnetic bead separation

• Confirm purity using antibodies against satellite cell markers (Pax7, integrin-α7)

• Analyze MYF5 expression by immunofluorescence, flow cytometry, or Western blot

Studying dynamics during regeneration:

• Implement injury models (cardiotoxin, BaCl₂, or mechanical injury) and harvest muscle at different time points

• Section tissues for immunohistochemistry with MYF5 antibodies

• Co-stain with proliferation markers (Ki67, BrdU) and other myogenic factors

• Quantify MYF5+ cells relative to regeneration stage

Reporter systems:
Researchers have developed MYF5 reporter systems to track expression in real-time:

• A CRISPR/Cas9-generated MYF5-GFP knock-in reporter human iPS cell line allows prospective identification and purification of myogenic progenitors

• These systems enable isolation of MYF5-GFP+ cells for characterization of differentiation potential

For optimizing antibody detection in regeneration studies, consider the dynamic expression pattern of MYF5—it's upregulated early during satellite cell activation and then downregulated during terminal differentiation.

How can MYF5 antibodies be used to investigate pathological conditions affecting muscle development?

MYF5 antibodies serve as valuable tools for investigating muscle pathologies:

Investigating MYF5 mutations in human disease:

• Recessive MYF5 mutations cause external ophthalmoplegia and rib anomalies

• Immunohistochemistry with specific antibodies can help determine if mutant MYF5 proteins localize correctly

• For the p.Gln8Leufs*86 frameshift mutation, antibodies targeting C-terminal epitopes would fail to detect the truncated protein, while N-terminal antibodies could still identify the mutant protein

• For the p.Arg95Cys missense mutation affecting the basic DNA-binding domain, ChIP assays combined with reporter experiments can assess DNA binding and transcriptional activity defects

Studying dysregulated muscle development:

• Comparative analysis of normal versus pathological samples using:

  • Quantitative Western blot to measure MYF5 protein levels

  • ChIP-seq to profile genome-wide binding patterns

  • Co-immunoprecipitation to identify altered protein-protein interactions

Therapeutic implications:

• In gene therapy approaches, antibodies can confirm successful expression of delivered MYF5 constructs

• For regenerative medicine applications using engineered myogenic progenitors, MYF5 antibodies help verify proper differentiation status

What are common pitfalls when working with MYF5 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with MYF5 antibodies:

Common issues and solutions:

Validation strategies:

• Positive controls: C2C12 myoblasts, primary myoblasts, or skeletal muscle tissue

• Negative controls: Non-muscle cells or MYF5-knockout models

• Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specificity

• Orthogonal validation: Confirm results with alternative detection methods (e.g., mRNA expression)

How do I validate MYF5 antibody specificity, particularly for new research models?

Thorough validation of MYF5 antibodies is essential, especially when working with novel research models:

Recommended validation workflow:

• Literature and data resources review:

  • Check manufacturer validation data including Western blots and immunostaining images

  • Review published literature using the specific antibody clone

• Molecular validation:

  • Western blot comparing control vs. MYF5-depleted samples

  • Test for appropriate molecular weight (~28 kDa predicted, often observed at ~39 kDa)

  • Confirm reduced signal after siRNA/shRNA knockdown

• Biological validation:

  • Compare expression patterns in differentiating muscle cells (expression should change with differentiation state)

  • Test in known positive tissues (skeletal muscle) and negative tissues

  • Co-localization with other nuclear transcription factors

• Advanced validation for new models:

  • For non-model organisms: Test antibodies raised against multiple epitopes

  • For unique applications: Recombinant expression of tagged MYF5 as positive control

  • For absolute confirmation: CRISPR/Cas9-engineered MYF5 knockout as negative control

• Cross-application validation:

  • Test antibody performance across multiple techniques (WB, IF, IHC)

  • Document optimal conditions for each application

What considerations are important when using MYF5 antibodies for ChIP-seq experiments?

ChIP-seq experiments with MYF5 antibodies require specific considerations for successful outcomes:

Critical protocol elements:

• Antibody selection:

  • Choose ChIP-validated antibodies with demonstrated specificity

  • Consider polyclonal antibodies for improved epitope accessibility in crosslinked chromatin

  • Monoclonal antibodies may provide higher reproducibility between experiments

• Fixation optimization:

  • Standard 1% formaldehyde for 10 minutes is typical, but MYF5 may require optimization

  • Test fixation times (8-15 minutes) to balance DNA-protein crosslinking and epitope preservation

• Controls and validation:

  • Include IgG control to establish background binding

  • Use biological controls (MYF5-negative cells) as true negative controls

  • Validate enrichment at known MYF5 target sites before sequencing (e.g., E-box-containing muscle gene promoters)

Data analysis considerations:

• MYF5 binds E-box motifs (CANNTG), particularly in muscle-specific gene regulatory regions

• Comparative analysis with MyoD ChIP-seq can help identify shared and distinct binding patterns

• MYF5 peaks correlate strongly with histone H4 acetylation, providing an additional validation metric

When interpreting MYF5 ChIP-seq data, remember that binding does not necessarily equate to strong transcriptional activation, as demonstrated by the differential transcriptional activity between MYF5 and MyoD despite similar binding patterns .

How can MYF5 antibodies be used in single-cell analysis of muscle development and regeneration?

Single-cell technologies offer powerful new approaches for studying MYF5 in heterogeneous muscle tissues:

Single-cell protein analysis:

• Mass cytometry (CyTOF):

  • MYF5 antibodies can be metal-conjugated for CyTOF analysis

  • Enables simultaneous detection of MYF5 with surface markers and other intracellular proteins

  • Provides quantitative measurement across large cell populations (>10⁶ cells)

• Single-cell Western blot:

  • Microfluidic platforms allow protein analysis at single-cell resolution

  • MYF5 antibodies can detect expression heterogeneity within myogenic populations

• Imaging mass cytometry/Multiplexed ion beam imaging:

  • Metal-conjugated MYF5 antibodies enable spatial analysis of expression in tissue sections

  • Preserves tissue architecture while providing single-cell resolution

Integration with transcriptomics:

• Paired single-cell RNA-seq and protein analysis (CITE-seq) using oligonucleotide-tagged antibodies

• Correlation of MYF5 protein levels with transcriptome-wide gene expression patterns

• Identification of distinct myogenic cell states based on MYF5 expression and co-expressed genes

These approaches are particularly valuable for studying the heterogeneity of satellite cell activation during regeneration and the progression of myogenic differentiation.

What are the challenges and opportunities in using MYF5 antibodies for studying induced pluripotent stem cell (iPSC) differentiation to muscle?

iPSC differentiation to muscle presents specific challenges for MYF5 antibody applications:

Challenges:

• Temporal dynamics:

  • MYF5 expression is transient during myogenic specification

  • Capturing expression requires precise timing of analyses

• Low frequency of spontaneous differentiation:

  • Spontaneous myogenic differentiation from iPSCs is inefficient

  • Detection requires sensitive antibodies and enrichment strategies

• Heterogeneous differentiation:

  • iPSC cultures often contain mixed cell populations

  • Distinguishing true myogenic cells from background requires specific markers

Innovative approaches:

• Reporter systems:

  • CRISPR/Cas9 knock-in MYF5-GFP reporters in human iPSCs enable prospective identification of myogenic progenitors

  • Reporter lines facilitate isolation of pure populations for downstream analysis

• Directed differentiation monitoring:

  • Flow cytometry with MYF5 antibodies can quantify efficiency of directed differentiation protocols

  • Immunofluorescence time course studies can optimize differentiation conditions

• Disease modeling:

  • Patient-derived iPSCs with MYF5 mutations can be studied using mutation-specific antibodies

  • Comparing wild-type and mutant MYF5 localization and function provides mechanistic insights

Verification strategies:

• Parallel analysis of MYF5 with other myogenic markers (PAX3, PAX7, MyoD)

• Functional validation of sorted MYF5+ cells through transplantation or in vitro differentiation assays

• Comparison with primary myogenic cells as reference standard